Shots:

• Celltrion completes its first step of developing an antiviral treatment against COVID-19 and aims to launch a rapid self-testing diagnostic kit- that has the potential of providing results within 15-20min
• Celltrion is expected to initiate clinical studies in Q3’20. Additionally- Celltrion plans to develop a ‘super Ab’ that may have the potential to attach and neutralize all kinds of coronavirus strains- including COVID-19 and SARS and enables further protection against unexpected mutations
• The kit will focus on the gene that encodes the surface spike (S) protein that the virus uses to enter human cells with its expected launch in summer this year and will be available in EU- following the CE mark. Celltrion intends to apply for device authorization from the FDA and other regulatory authorities after acquiring relevant data

Click here ­to­ read full press release/ article 

 Ref: Celltrion  | Image: Celltrion